Scalper1 News
Biotech Raptor (RPTP) plunged in early trading Monday after its drug candidate failed a trial in pediatric fatty liver disease. Raptor said its phase two trial of its candidate RP103 in nonalcoholic steatohepatitis (NASH) failed to meet its endpoint of a two-point improvement in a fatty-liver-disease scoring system, and no worsening of fibrosis, or scarring of the liver. “We’re disappointed with this outcome, given the paucity of treatment for Scalper1 News
Scalper1 News